Pediatric hemoptysis with pulmonary hemorrhage and respiratory failure.

Am J Emerg Med

Department of Emergency Medicine, MetroHealth Medical Center, Cleveland, OH, USA.

Published: June 2008

Hemoptysis is a rare complaint in the pediatric population. It is most commonly of infectious etiology and is rarely life threatening. However, there are rare life-threatening causes of pediatric hemoptysis, which should be included in the differential diagnoses of children presenting to the emergency department (ED) with this complaint. This study aims to present a case of pediatric hemoptysis, briefly discuss the differential diagnosis, and present a review of the causes, manifestations, and treatment for hemoptysis secondary to diffuse alveolar hemorrhage (DAH).

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajem.2007.10.035DOI Listing

Publication Analysis

Top Keywords

pediatric hemoptysis
12
pediatric
4
hemoptysis pulmonary
4
pulmonary hemorrhage
4
hemorrhage respiratory
4
respiratory failure
4
hemoptysis
4
failure hemoptysis
4
hemoptysis rare
4
rare complaint
4

Similar Publications

Purpose: To investigate the clinical characteristics of Mycoplasma pneumoniae (MP) pneumonia (MPP) combined with pulmonary embolism (PE) in children.

Methods: 291 hospitalized pediatric cases with MPP were enrolled from January 2018 to May 2024 and divided into the PE group (141 cases) and non-PE control group (150 cases). Clinical data of both groups were analyzed and compared.

View Article and Find Full Text PDF
Article Synopsis
  • Hemoptysis, the coughing up of blood, can stem from various serious underlying conditions, but often involves high-pressure bronchial arteries; Bronchial artery embolization (BAE) is typically the first-line treatment despite varying long-term success rates.
  • A 12-year-old boy with a history of massive hemoptysis underwent multiple BAEs and recent imaging confirmed the location of previous coils; however, he experienced another episode where traditional intervention was complicated by prior treatments.
  • The medical team opted for a thoracoscopic approach, successfully isolating and ligating the problematic vessel, leading to the patient's stabilization and discharge after four days.
View Article and Find Full Text PDF

A 20-year-old male underwent diagnostic testing due to unexplained shortness of breath and chest discomfort. He had no previous medical problems and was not taking any medications. Initial evaluations included cardiopulmonary exercise testing (CPET), which yielded results that were reported as normal.

View Article and Find Full Text PDF

Thrombocytopenia is common in the critical phase of dengue due to decreased production from the bone marrow and increased peripheral destruction of platelets. Platelet count improves with resolution of the disease. However, further evaluation is required if thrombocytopenia persists for a longer period following dengue infection.

View Article and Find Full Text PDF

Background: Aztreonam was approved by the FDA for treating Gram-negative infections, including metallo-β-lactamase producers. This study extensively evaluated aztreonam-related adverse events (AEs) from the FDA Adverse Event Reporting System (FAERS) database for a better understanding of toxicities.

Methods: The signals of aztreonam-related AEs were quantified using disproportionality analyses, like reporting odds ratio, proportional reporting ratio, Bayesian confidence propagation neural network, and multi-item gamma Poisson shrinker algorithms.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!